525 related articles for article (PubMed ID: 23219069)
1. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
Kang HM; Koh HJ
Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
[TBL] [Abstract][Full Text] [Related]
2. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
4. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome.
Kang HM; Koh HJ; Lee CS; Lee SC
Am J Ophthalmol; 2014 Mar; 157(3):598-606.e1. PubMed ID: 24269378
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy combined with intravitreal injection of vascular endothelial growth factor antibody for polypoidal choroidal vasculopathy.
Moon SW; Kim MS; Kim ES; Yu SY; Kwak HW
Ophthalmologica; 2011; 225(3):169-75. PubMed ID: 21273795
[TBL] [Abstract][Full Text] [Related]
6. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
9. Prognostic factors for visual outcome after intravitreal anti-VEGF injection for naive myopic choroidal neovascularization.
Yoon JU; Kim YM; Lee SJ; Byun YJ; Koh HJ
Retina; 2012 May; 32(5):949-55. PubMed ID: 22534553
[TBL] [Abstract][Full Text] [Related]
10. Two-year results of photodynamic therapy combined with intravitreal anti-vascular endothelial growth factor for polypoidal choroidal vasculopathy.
Kim M; Kim K; Kim DG; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(4):205-13. PubMed ID: 21893965
[TBL] [Abstract][Full Text] [Related]
11. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
Lazic R; Gabric N
Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
[TBL] [Abstract][Full Text] [Related]
12. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia.
Parodi MB; Iacono P; Papayannis A; Sheth S; Bandello F
Arch Ophthalmol; 2010 Apr; 128(4):437-42. PubMed ID: 20142520
[TBL] [Abstract][Full Text] [Related]
13. Analysis of outcomes for intravitreal bevacizumab in the treatment of choroidal neovascularization secondary to ocular histoplasmosis.
Cionni DA; Lewis SA; Petersen MR; Foster RE; Riemann CD; Sisk RA; Hutchins RK; Miller DM
Ophthalmology; 2012 Feb; 119(2):327-32. PubMed ID: 22133795
[TBL] [Abstract][Full Text] [Related]
14. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis.
Parodi MB; Iacono P; Kontadakis DS; Zucchiatti I; Cascavilla ML; Bandello F
Arch Ophthalmol; 2010 Sep; 128(9):1100-3. PubMed ID: 20837791
[TBL] [Abstract][Full Text] [Related]
16. Photodynamic therapy with or without intravitreal bevacizumab for polypoidal choroidal vasculopathy: two years of follow-up.
Lee YA; Yang CH; Yang CM; Ho TC; Lin CP; Huang JS; Chen MS
Am J Ophthalmol; 2012 Nov; 154(5):872-880.e2. PubMed ID: 22831838
[TBL] [Abstract][Full Text] [Related]
17. ANTIANGIOGENICS IN CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH LASER IN CENTRAL SEROUS CHORIORETINOPATHY.
Chhablani J; Pichi F; Silva R; Casella AM; Murthy H; Banker A; Nowilaty SR; Carrai P; Nucci P; Arevalo JF;
Retina; 2016 May; 36(5):901-8. PubMed ID: 27115855
[TBL] [Abstract][Full Text] [Related]
18. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
Peiretti E; Caminiti G; Serra R; Querques L; Pertile R; Querques G
Retina; 2018 Aug; 38(8):1526-1532. PubMed ID: 28699928
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
20. Effects of choroidal vascular hyperpermeability on anti-vascular endothelial growth factor treatment for polypoidal choroidal vasculopathy.
Cho HJ; Kim HS; Jang YS; Han JI; Lew YJ; Lee TG; Kim CG; Kim JW
Am J Ophthalmol; 2013 Dec; 156(6):1192-1200.e1. PubMed ID: 24011522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
